RAD-140 is studied for non-steroidal selective receptor modulator activity, GW-501516 for metabolic pathway modulation relevant to glucose transport and lipid metabolism research, and MK-677 for growth hormone secretagogue properties and receptor system interactions. Combined research protocols allow investigators to examine how these three distinct mechanisms may interact within multi-pathway body composition and metabolic research models.

Cell-based receptor binding assays, metabolic flux measurements (such as glucose uptake and lipid oxidation assays), and growth hormone pathway signalling assays (such as IGF-1 level measurement in relevant experimental models) are standard methods for studying this combination, typically run across single-compound and combined-compound treatment arms for comparative analysis.

Factorial or staggered experimental designs incorporating single-compound, paired-compound, and full three-compound treatment arms allow researchers to isolate the contribution of each compound and identify any combination-specific effects on selected research endpoints, a standard approach when studying multi-pathway compound combinations.